Provided is a degradable microparticle with a grain size in a range of 2 micrometers to 1400 micrometers, and the degradable microparticle comprises poly(glycerol sebacate), poly(glycerol maleate), poly(glycerol succinate-co-maleate), poly(glycerol succinate), poly(glycerol malonate), poly(glycerol glutarate), poly(glycerol adipate), poly(glycerol pimelate), poly(glycerol suberate), poly(glycerol azelate), or any combination thereof. A degradable product produced from the degradable microparticles can obtain the desired degradation effect and can be produced by chemical synthesis to reduce the production cost. With these advantages, the applicability of the degradable microparticles is improved.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

This invention relates to a biodegradable polyester which is particularly suitable for use in the manufacture of mass-produced articles characterised by excellent mechanical properties, in particular high tensile strength, elongation and tensile modulus, associated with a high barrier property against oxygen and carbon dioxide.

Residence structures, systems, and related methods are generally provided. Certain embodiments comprise administering (e.g., orally) a residence structure to a subject (e.g., a patient) such that the residence structure is retained at a location internal to the subject for a particular amount of time (e.g., at least about 24 hours) before being released. The residence structure may be, in some cases, a gastric residence structure. In some embodiments, the structures and systems described herein comprise one or more materials configured for high levels of active substances (e.g., a therapeutic agent) loading, high active substance and/or structure stability in acidic environments, mechanical flexibility and strength in an internal orifice (e.g., gastric cavity), easy passage through the GI tract until delivery to at a desired internal orifice (e.g., gastric cavity), and/or rapid dissolution/degradation in a physiological environment (e.g., intestinal environment) and/or in response to a chemical stimulant (e.g., ingestion of a solution that induces rapid dissolution/degradation). In certain embodiments, the structure has a modular design, combining a material configured for controlled release of therapeutic, diagnostic, and/or enhancement agents with a structural material necessary for gastric residence but configured for controlled and/or tunable degradation/dissolution to determine the time at which retention shape integrity is lost and the structure passes out of the gastric cavity. For example, in certain embodiments, the residence structure comprises a first elastic component, a second component configured to release an active substance (e.g., a therapeutic agent), and, optionally, a linker. In some such embodiments, the linker may be configured to degrade such that the residence structure breaks apart and is released from the location internally of the subject after a predetermined amount of time.

Disclosed herein are processes of making furan-based polyamides using solvent-free melt condensation of a diamine and an ester derivative of 2,5-furandicarboxylic acid with a C.sub.2 to C.sub.12 aliphatic diol or a polyol. The processes comprise a) forming a reaction mixture by mixing one or more diamines, a diester comprising an ester derivative of 2,5-furandicarboxylic acid with a C.sub.2 to C.sub.12 aliphatic diol or a polyol, and a catalyst, such that the diamine is present in an excess amount of at least 1 mol % with respect to the diester amount; and b) melt polycondensing the reaction mixture in the absence of a solvent at a temperature in the range of 60° C. to a maximum temperature of 250° C. under an inert atmosphere, while removing alkyl alcohol to form a furan-based polyamide, wherein the one or more diamines comprises an aliphatic diamine, an aromatic diamine, or an alkylaromatic diamine.

Method for obtaining biodegradable polymers that has a stage of esterification and/or transesterification and amidation reaction, a stage of prepolycondensation, a stage of polycondensation, a stage of extraction and a stage of drying, eliminating the use of chain extenders. The polymer can achieve all the range of viscosities desired and with an improved colour compared to the polymer from other methods, where chain extenders are used, provide a more efficient process, that is environmentally cleaner and safer for the operatives.

Disclosed are a spiral coated stent with controllable gradient degradation, a preparation method thereof and an application thereof. The spiral coated stent with controllable gradient degradation is composed of a degradable medical polyurethane and a degradable magnesium alloy material, wherein the degradable medical polyurethane contains a following chemical structure: PCL-PEG-PCL, wherein a molecular weight of the PEG is 200 to 1,000 and the molecular weight of the PCL is 200 to 10,000, and the degradable magnesium alloy material is of a spiral stent structure; and physical properties of the spiral coated stent with controllable gradient degradation need to satisfy the following technical parameters that: a breaking strength needs to be no less than 1 N, a pressure resistance needs to be no less than 2 N, and a degradation characteristic of the magnesium alloy after surface treatment shows gradient degradation with different time.

Tumor resection is commonly practiced to prevent the progression of cancer. However, there are post-surgery concerns including the formation of a void that can allow cancer cells to escape at the surgery site, which increases the risk of metastasis. To counter this challenge, an embodiment includes a polyurethane-based shape memory foam as a tissue void-filling device that can also release anti-cancer drugs. Such foams may activate at body temperature and become malleable. Such properties may enable the foam to be shaped to precisely seal the tissue void and then serve as a drug-eluting device. Based on the drug composition with poly vinyl alcohol (PVA), the drug release profile from the foam may be altered depending on the application.

Foam compositions, cushions, and related methods of manufacture are disclosed. The foam composition or cushion include (a) polymer that includes (i) a maximum of 60% polyol that includes multiple hydroxyl groups, and (ii) less than 50% isocyanate, (b) at least 40% filler suspended in the polymer, and (c) a plurality of digesters suspended in the polymer.